Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Struman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 3, 1995
Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactinG D'Angelo, I Struman, J Martial, et al.
European Journal of Biochemistry|June 1, 1993
The addition of nine residues at the C-terminus of human prolactin drastically alters its biological propertiesV Goffin, I Struman, E Goormaghtigh, et al.
Gene|September 21, 1992
Stabilization of T7-promoter-based pARHS expression vectors using the parB locusL De Moerlooze, I Struman, A Renard, et al.
Cancer Research|October 5, 2001
Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) miceF Bentzien, I Struman, J F Martini, et al.
Endocrinology|September 2, 1998
Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expressionH Lee, I Struman, C Clapp, et al.
The Journal of Biological Chemistry|December 23, 1994
Evidence for a second receptor binding site on human prolactinV Goffin, I Struman, V Mainfroid, et al.
Revue Medicale De Liege|August 11, 2011
[Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]J Collignon, I Struman, S Tabruyn, et al.
Revue Medicale De Liege|March 8, 2021
[Idiopathic pulmonary fibrosis : from biomarkers to new therapeutic areas]J Guiot, M Henket, M S Njock, et al.
Molecular Endocrinology (Baltimore, Md.)|October 24, 2000
The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activationJ F Martini, C Piot, L M Humeau, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 1999
Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesisI Struman, F Bentzien, H Lee, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Proceedings of the National Academy of Sciences of the United States of America|July 3, 1995
Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactinG D'Angelo, I Struman, J Martial, et al.
European Journal of Biochemistry|June 1, 1993
The addition of nine residues at the C-terminus of human prolactin drastically alters its biological propertiesV Goffin, I Struman, E Goormaghtigh, et al.
Gene|September 21, 1992
Stabilization of T7-promoter-based pARHS expression vectors using the parB locusL De Moerlooze, I Struman, A Renard, et al.
Cancer Research|October 5, 2001
Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) miceF Bentzien, I Struman, J F Martini, et al.
Endocrinology|September 2, 1998
Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expressionH Lee, I Struman, C Clapp, et al.
The Journal of Biological Chemistry|December 23, 1994
Evidence for a second receptor binding site on human prolactinV Goffin, I Struman, V Mainfroid, et al.
Revue Medicale De Liege|August 11, 2011
[Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]J Collignon, I Struman, S Tabruyn, et al.
Revue Medicale De Liege|March 8, 2021
[Idiopathic pulmonary fibrosis : from biomarkers to new therapeutic areas]J Guiot, M Henket, M S Njock, et al.
Molecular Endocrinology (Baltimore, Md.)|October 24, 2000
The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activationJ F Martini, C Piot, L M Humeau, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 1999
Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesisI Struman, F Bentzien, H Lee, et al.
Pageof 2